Contact Us
Drug Search Results
More Filters [+]

Avacincaptad pegol

Alternative Names: avacincaptad pegol, Zimura
Latest Update: 2024-12-10
Latest Update Note: Clinical Trial Update

Product Description

Avacincaptad pegol, a polyethylene glycol-conjugated oligonucleotide, is a potent C5 inhibitor delivered via a 100 µl intravitreal injection.  (Sourced from: https://iovs.arvojournals.org/article.aspx?articleid=2772902)

Mechanisms of Action: C5 Inhibitor

Novel Mechanism: No

Modality: Nucleic Acid

Route of Administration: Injection

FDA Designation:
Breakthrough Therapy - Geographic Atrophy
Fast Track - Geographic Atrophy|Macular Degeneration
Priority Review - Geographic Atrophy *

Approval Status: Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: IVERIC bio
Company Location: NEW YORK NY 10001
Company CEO: Glenn P. Sblendorio
Additonal Commercial Interests: DelSiTech

Clinical Description

Map of Global Clinical Trials for Avacincaptad pegol

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Croatia, Czech Republic, Estonia, France, Germany, Hungary, Israel, Italy, Latvia, Poland, Spain, United Kingdom, United States

Active Clinical Trial Count: 6

Highest Development Phases

Phase 3: Geographic Atrophy|Macular Degeneration

Phase 2: Stargardt Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
STGD1

P2

Active, not recruiting

Stargardt Disease|Macular Degeneration

2025-04-30

ISEE2009

P3

Unknown Status

Geographic Atrophy

2025-04-10

GATHER2

P3

Active, not recruiting

Macular Degeneration|Geographic Atrophy

2025-03-31

GATHER2 OLE

P3

Active, not recruiting

Geographic Atrophy

2025-03-21

Recent News Events

Date

Type

Title

09/24/2024

News Article

 Aviceda Therapeutics Completes Enrollment of Phase 2b SIGLEC Study Assessing the Safety and Efficacy of AVD-104 for Geographic Atrophy Secondary to AMD

09/10/2024

News Article

 Aviceda Therapeutics Announces Addition of Erin Lavelle to Board of Directors

07/09/2024

News Article

 Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

05/01/2024

News Article

 Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions